



An update on NextCell Pharma and Nordic Tech House

NextCell Pharma's (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders' preferential rights.

NextCell Pharma buys services from Nordic Tech House to increase exposure of NextCell Pharma and Cellaviva, both to inform about its development of stem cell therapies and stem cell saving and to optimize the digital messaging for the next 2 years. For its Nordic Tech House is paid with shares in NextCell Pharma AB through a directed issue.

The value of the services is SEK 1 995 000 and is paid in shares (10-day average closing price after entering into agreement, 2018-03-13). The share price of the issue will be 5,767 SEK (+1% compared to the closing price on the 2018-03-13 contract day), giving Nordic Tech House a total of about 345,934 shares, equivalent to 3.91% of votes and capital in NextCell Pharma.

The issue is scheduled for March / April and shares will be held on an escrow account to be transferred to Nordic Tech House half-yearly in arrears. All shares in the issue are covered by a lock-up during the term of the agreement.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.